IP Library Granted Patent US 7,662,609
Granted Patent B2
US 7,662,609 · App. 10/531,402 · Granted Feb 16, 2010

Patent

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,662,609
App. No.
10/531,402
Granted
Feb 16, 2010
Kind
B2
Abstract

The present invention provides an Ecoli host cell expressing a recombinant antibody characterized in that the Ecoli host cell has been genetically modified in order to change at least one physical property of one or more Ecoli proteins which in the wild type copurify with said recombinant antibody.

Claims (7)

1. An E. coli host cell expressing a recombinant antibody wherein the E. coli host cell has been genetically modified in order to change the isoelectric point of the E. coli Phosphate binding protein (PhoS/PstS) wherein the isoelectric point has been altered by: (a) the addition of a poly-aspartic acid tag to the C-terminus of the Phosphate binding protein and/or (b) changing one or more of the amino acid residues located on the surface of the E. coli Phosphate binding protein (PhoS/PstS) by (i) substituting one or more lysine and/or arginine residues with aspartic acid or a glutamic acid or (ii) substituting one or more aspartic acid and/or glutamic acid residues with lysine or arginine.

2. The host cell of claim 1 where the isoelectric point of the Phosphate binding protein (PhoS/PstS) has been reduced by substituting one or more lysines at residues 110, 265, 266 or 318 with glutamine or aspartic acid.

3. The host cell of claim 2 where the isoelectric point of the Phosphate binding protein (PhoS/PstS) has been reduced further by the addition of a poly-aspartic acid tag to the C-terminus.

4. The host cell of claim 1 where the isoelectric point of the Phosphate binding protein (PhoS/PstS) has been reduced by substituting the lysines at residues 265 and 266 with glutamine and by the addition of a poly-aspartic acid tag to the C-terminus.

5. The host cell of claim 1 where the isoelectric point of the Phosphate binding protein (PhoS/PstS) has been reduced by substituting the lysines at residues 110, 265 and 266 with glutamine and by the addition of a poly-aspartic acid tag to the C-terminus.

6. The host cell of claim 1 where the recombinant antibody is a Fab or a Fab′ fragment.

7. A method of manufacturing a recombinant antibody which comprises fermenting a host cell according to claim 1 .

Assignments (3)
CONFIRMATORY ASSIGNMENT Recorded Jun 10, 2016
From: UCB PHARMA, S.A.
To: UCB BIOPHARMA SPRL
Reel/Frame 038953/0312 →
CON Recorded Sep 4, 2008
From: CELLTECH R&D LIMITED
To: UCB PHARMA S.A.
Reel/Frame 021478/0274 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 30, 2006
From: HUMPHREYS, DAVID PAUL; CHAPMAN, ANDREW PAUL; ROBINSON, MARTYN KIM; SPITALI, MARIANGELA
To: CELLTECH R & D LIMITED
Reel/Frame 017412/0167 →